si-544

About selectION Therapeutics

selectION Therapeutics is pioneering a new class of autoimmune therapies with its lead candidate, si-544, a first-in-class Kv1.3 blocker. The drug has successfully completed Phase 1b proof-of-concept trials in psoriasis and atopic dermatitis, demonstrating safety, tolerability, and early efficacy signals. The company is now planning Phase 2 studies, positioning si-544 as a potential disease-modifying, systemic first-line treatment with broad applicability across over 80 T cell-mediated autoimmune indications. Backed by strong scientific rationale and a management team with industry experience, selectION is targeting a massive, underserved market dominated by non-specific immunosuppressants.

Therapeutic Areas